| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President & CEO
1 company
Travis C Mickle last filed a Form 4 in May 2022, as President & CEO at ZVRA. From April 2015 to May 2022, the filings on record show 12 open-market purchases and 0 sales. Travis C Mickle's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Travis C Mickle a below-average insider score of 37/100, based on 4 past trades. Over a 12-month horizon, 25.0% of those trades were profitable, with an average 12-month return of -35.6%.
At the last filing, the largest reported position was 11,034 shares of ZVRA. Net of sales, the ZVRA filings show accumulation of 229,200 shares.
Shares as reported in the last Form 4 for each company; the most recent is from May 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 17, 2016 | ZVRA Zevra Therapeutics, Inc. | President & CEO | Buy | 5,000 | $4.95 | $24,750.00 | +243.9% | |
| Mar 29, 2016 | ZVRA Zevra Therapeutics, Inc. | President & CEO | Buy | 2,450 | $14.57 | $35,703.30 | +7.9% |